Attempts to treat BRAF variant colorectal cancer with single-agent BRAF inhibitors have achieved limited success.6 Evidence suggests that rapid feedback activation of the epidermal growth factor receptor (EGFR)7 may be a factor in the poor response to single-agent BRAF inhibitors. The gene discussed is EGFR; the disease is colorectal cancer.